Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Pain Test that Stratifies Patients for Optimal Therapy Seeks Partners

Published: Tuesday, February 19, 2013
Last Updated: Monday, February 18, 2013
Bookmark and Share
Algotect device measures an increased pain response to a cold stimulus.

A novel patented technology (Algotect) has been developed to accurately identify patients who are cold hyperalgesic and require specific pain management.

A recent Australian clinical trial (n=80) conducted with funding from a multi-national pharmaceutical company clearly segmented a group of knee osteoarthritis patients into those that had more pain, more disability, more widespread hyperalgesia and more neuropathic pain symptoms.

This group did not respond well to a standard non-steroidal medication. Cold hyperalgesic groups have been identified for a range of painful conditions and it is likely that these patients require more specific pain management.

More than 1.5 billion people worldwide suffer from chronic pain (American Academy of Pain Medicine) and around 100 million Americans suffer chronic pain (Institute of Medicine of the National Academies).

In developed countries about 30-40% of the population suffer pain from musculoskeletal and joint disorders plus an additional 30% suffer neck and back pain (International Association for the Study of Pain).

A chronic pain survey by the American Pain Foundation in 2006 (n=303) revealed 51% had little or no control over their pain and 59% reported an impact on their quality of life. The Algotect device identifies those most at risk of poor outcomes.

Managing Director and co-founder Prof Tony Wright comments, “There is an unmet medical need for a simple diagnostic test such as Algotect. Determining early on those patients who will develop chronic pain and providing them with more effective treatment will generate significant health outcomes for individuals and reduce costs on a global scale.”

The Algotect device measures an increased pain response to a cold stimulus (cold hyperalgesia). Patients who have cold hyperalgesia have more pain and more disability than others.

The prototype uses a transdermal patch that activates TRPM8 receptors in peripheral tissues over a 10-minute period. Patients indicate their sensory response via a computer interface.

A patented algorithm quantifies the sensory response and delivers a scored report indicating if their pain can be managed effectively through simple analgesics or if more comprehensive pain management is required.

Algometron seeks partners interested in commercially developing the innovative device, which provides real time, cost effective information to support clinicians, researchers, drug development and clinical trials.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!